hit counter
ARCA biopharma, Inc. (ABIO) Stock News Sentiment & Price - Sentifly
ABIO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ARCA biopharma, Inc. (ABIO)

USA
Biotechnology
NASDAQ
ABIO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ABIO Latest news
GlobeNewsWire
Neutral
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
2021-11-09 16:15

WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Tom Keuer, Chief Operating Officer, will present at the Q4 Virtual Investor Summit being held November 16-17, 2021.

GlobeNewsWire
Neutral
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-02 16:15

WESTMINSTER, Colo., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2021 financial results and provided a corporate update.

Benzinga
Positive
ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged
2021-10-29 06:26

The Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis for ARCA biopharma Inc's (NASDAQ: ABIO) ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinant protein for COVID-19. Based on the review of approximately 75% of the projected final efficacy and safety data, DSMC recommended completing the trial with no modifications to the trial design.

GlobeNewsWire
Neutral
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data
2021-10-28 16:30

WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the ASPEN-COVID-19 Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with severe COVID-19. The Company announced that the Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis and, based on the DSMC's review of approximately 75% of the projected final efficacy and safety data, recommended completion of the clinical trial with no modifications to the trial design. The rNAPc2 development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).   The Company now anticipates completion of target enrollment of 160 patients by year end 2021 and reporting of topline data in the first quarter of 2022.

GlobeNewsWire
Neutral
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
2021-09-16 08:30

WESTMINSTER, Colo., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. The patient was enrolled in Brazil. ARCA also plans to enroll patients from Argentina and is currently enrolling patients at multiple sites in the United States. The international Phase 2b trial is approximately 75% enrolled as of this date. The Company currently anticipates topline trial data in the fourth quarter of 2021.

GlobeNewsWire
Neutral
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
2021-08-16 08:05

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021.

GlobeNewsWire
Neutral
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-04 16:15

WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update.

GlobeNewsWire
Neutral
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
2021-07-13 08:00

WESTMINSTER, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.

GlobeNewsWire
Neutral
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th
2021-07-09 08:00

WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer, Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.

PennyStocks
Positive
Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List
2021-07-07 15:19

Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?

Loading more news...